(Registrieren)

TVM Life Science Ventures VII Raises US $201.6 Million at Final Closing

Geschrieben am 06-10-2014

Montreal/Munich (ots) - Fund focuses on achieving human clinical
proof-of-concept for early stage drug development projects, following
a capital efficient investment approach in collaboration with Lilly

TVM Capital Life Science, one of the leading life science venture
capital firms in Canada, the United States and Europe, today
announced the final closing of its latest fund, TVM Life Science
Ventures VlI, surpassing its target with more than $200 million
raised from a broad mix of investors, including cornerstone investors
Teralys Capital and Eli Lilly and Company. Other investors include
the Business Development Bank of Canada, the Minnesota Life Insurance
Company, CD Venture and FondAction. The fund also attracted
significant investment from other pharmaceutical companies such as
Bukwang Pharma of South Korea.

TVM Life Science Ventures VII is a unique collaboration between
TVM Capital Life Science and industry to finance and access
innovation, in addition to being a way to manage risk and share
reward. The fund acquires early-stage molecules from pharmaceutical
or biotechnology companies around the world, and then finances a
virtual project-focused-company ("PFC") for each of these molecules.
The objective is to develop each molecule through proof-of-concept
(one or more clinical studies designed to determine whether a
molecule has the potential to work in patients). If the molecule
shows efficacy, the molecule and/or development rights are offered
for sale to biopharmaceutical companies.

As an added benefit, these project-focused-companies have the
option to select Chorus, a virtual drug development organization
within Lilly?s Global External Research and Development group. Chorus
provides access to world-class scientists who can produce
high-quality data packages through the implementation of lean and
focused drug development plans, at the direction of the
project-focused-companies, that help to determine proof-of-concept.

"The high-quality of the investors in TVM Life Science Ventures
VII is a testament to TVM Capital?s strong 30-year track record of
identifying promising life sciences projects and companies and
supplying them with access to the scientific, capital and management
resources critical for success," said Dr. Hubert Birner, a managing
partner of TVM Capital?s Life Science practice. "The fund invests
mainly in Canada, the United States, Germany and Western Europe, and
is advised by a dedicated team of investment professionals based in
Montreal and Munich."

Dr. Luc Marengere, a managing partner of the firm added, "The
fund's first investments, including Kaneq Bioscience, GLWL Research,
Ixchelsis, PRCL Research, and FAAH Pharma, showcase the fund?s
strength in identifying innovative therapies, funding them, and
advancing them through this innovative model. Through TVM Life
Science Ventures VII, important new treatment options for patients
are progressing for disease areas such as Type 2 diabetes, men?s
health, inflammation, and pain. The fund targets a total of 12 to 15
project-focused-companies and four to five traditional, syndicated
venture investments."

"We are excited by the potential for this novel venture fund,
working with a diversified group of project-focused-companies, to
help address significant unmet medical needs," said Darren Carroll,
vice president of corporate business development at Lilly. "Lilly has
pioneered the use of independent external financing sources and
innovative business models, such as the collaboration with TVM Life
Science Ventures VII, to supplement our core R&D investment strategy,
leverage research investments, and to help reduce the risks of
research."

"TVM Life Science Ventures VII plays a significant role with
entrepreneurs and inventors by providing them access to a global
network of strategic partners, technologies and co-investors," said
Jacques Bernier, managing partner of Teralys Capital. "We are proud
to have played a pivotal role in the formation of this fund."

About TVM Capital Life Science

TVM Capital Life Science is providing venture capital to the
international pharmaceutical, biopharmaceutical and medical
technology industries with more than 30-years of transatlantic
investment track record and in excess of US$1.3bn under management.
The life science team boasts more than 120 investments and over 90
exits in the last 30 years, including more than 40 initial public
offerings on all major U.S. and European stock exchanges, and
combines long-standing international investment and company building
experience with their track record of dedicated board work, extensive
global networks in the world of life science research and product
development and a direct knowledge of the local markets. TVM Capital
Life Science currently invests from its 7th fund generation, TVM Life
Science Ventures VII, with an integrated team of investment
professionals. Fund generations III to VI are managed by managing
partners, Dr. Helmut M. Schühsler and Dr. Hubert Birner out of the
Munich office. The new fund TVM LSV VII is advised by Dr. Hubert
Birner and Dr. Luc Marengere out of Munich and Montreal. The fund?s
general partner resides in Jersey Channel Island. www.tvm-capital.com
or www.tvm-lifescience.com

About TVM Capital Group

TVM Capital is a group of globally acting venture capital and
private equity firms with an operating track record of 30 years.
Investment teams have financed more than 250 emerging companies
across several industries since 1984. During the last 15 years the
firm has become increasingly specialized in the most attractive and
high-growth verticals in the broader healthcare markets, with focus
areas in financing innovative products and technologies in the
European and U.S. biopharmaceutical and medical device markets, as
well as healthcare services in the Middle East and India. TVM Capital
funds operate globally with dedicated life science venture capital
funds advised by group members TVM Life Science Management in
Montréal and in Munich, and its healthcare private equity fund
managed by TVM Capital Healthcare Partners out of Dubai.

www.tvm-capital.com



For additional information, please contact:
Dr. Hubert Birner, Managing Partner, TVM Capital Life Science:
birner@tvm-capital.com: +1 514 931 4 111 or +49 89 998 992-0

Dr. Luc Marengere, Managing Partner, TVM Capital Life Science:
marengere@tvm-capital.com: +1 514 931 4 111

General Partner
TVM Life Science Ventures VII (GP)
Ltd.
11-15 Seaton Place,
St Helier, Jersey
JE4 0QH, Channel Islands

Investment Advisor
TVM Life Science
Management Inc.
2 Place Alexis Nihon, Suite
902, 3500 Blvd De
Maisonneuve West,
Westmount, Montréal, QC
H3Z 1X5, Canada

TVM Life Science
Management GmbH
Ottostrasse 4
80333 Munich, Germany


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

550665

weitere Artikel:
  • Saxo Launches USD 9,000 Trading Competition on TradingFloor.com Hellerup, Denmark (ots/PRNewswire) - Saxo Bank, the trading and investment specialist, has launched Saxo Trade Challenge, a trading competition open to Saxo Bank A/S clients with a minimum funding of USD 2,000 equivalent by 26 October. Saxo Trade Challenge will reward the top three performing traders on its award-winning, multi-asset social trading site, TradingFloor.com, over a seven week period, from 27 October to 18 December. The prize pool for the competition totals USD 9,000, with first, second and third place mehr...

  • DTB: Immobilienerwerber zahlen 12 Prozent weniger als noch vor einem Jahr (FOTO) Lübeck (ots) - Dr. Klein Trendindikator Baufinanzierung 08/2014 Stephan Gawarecki, Vorstandssprecher Dr. Klein & Co. AG, berichtet über aktuelle Trends in der Baufinanzierung und kommentiert die Ergebnisse des Dr. Klein Trendindikators Baufinanzierung (DTB). Nach einem leichten Rückgang in den letzten Monaten hat der durchschnittliche Tilgungssatz für eine Baufinanzierung mit 2,50 Prozent einen neuen Höchstwert erreicht. So viel haben Immobilienerwerber noch nie (durchschnittlich) getilgt. Und während die durchschnittliche mehr...

  • BVR zum Weltspartag: Sparquote langfristig rückläufig (FOTO) Berlin (ots) - Die Sparquote der privaten Haushalte in Deutschland wird mittel- bis langfristig zurückgehen. Zu diesem Ergebnis kommt der Bundesverband der Deutschen Volksbanken und Raiffeisenbanken (BVR) in seiner aktuellen Studie zum Weltspartag, der in diesem Jahr am 30. Oktober begangen wird. "Die demografische Entwicklung bewirkt einen Rückgang der Sparquote in Deutschland. Ich rechne damit, dass die Quote bis zum Jahr 2025 auf unter 7 Prozent fallen wird", analysiert BVR-Vorstand Dr. Andreas Martin. Ursächlich für die Entwicklung mehr...

  • Continentale Versicherungsverbund: Mit PflegeGarant früh in die private Vorsorge einsteigen und dann flexibel ausbauen Dortmund (ots) - Preiswerter Einstieg in die private Pflegevorsorge - mit allen Optionen für die Zukunft: Mit der neuen Produktlinie PflegeGarant bietet die Continentale Krankenversicherung a.G. ein hervorragendes Preis-Leistungs-Verhältnis und eine hohe Flexibilität. Damit können Vermittler ihren Kunden je nach Bedarf und Budget eine optimale private Absicherung anbieten, die künftigen Bedürfnissen angepasst werden kann. So kann etwa ein 30-jähriger Kunde bereits für weniger als 10 Euro einsteigen. Die Produktlinie besteht aus drei mehr...

  • Jahresabschluss 2013: ExtraEnergie kann Ergebnis fast verdoppeln Neuss (ots) - Nach dem äußerst erfolgreichen Geschäftsjahr 2012, in dem die Umsatzzahlen die Milliardenmarke überschritten, setzt die ExtraEnergie GmbH den positiven Wachstumstrend weiter fort und kann 2013 ihr Ergebnis nahezu verdoppeln. Dies bestätigt der Jahresabschluss zum Geschäftsjahr 2013, der erfolgreich von der internationalen Wirtschaftsprüfungsgesellschaft BDO AG geprüft wurde. Die Extra-Gruppe weist im vergangenen Jahr einen Umsatz von 1,6 Milliarden Euro aus und kann somit den Vorjahreswert (1,1 Milliarde Euro) mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht